Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Most infants infected with HIV through mother-to-child transmission (MTCT, or perinatal
transmission) become infected during labor and delivery. The purpose of this study is to test
the safety and tolerability of a single dose of tenofovir disoproxil fumarate (TDF) or
emtricitabine/TDF (FTC/TDF) given at the time of labor to HIV infected pregnant women and to
their newborn infants.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir